MDGL

Madrigal Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $13.36B and 528 employees. The company's revenue has grown significantly, reaching $740.64M in its trailing twelve months (TTM). The company's financial health is a concern, with net income and EBITDA both reporting significant losses at -$289,124,992 and -$306,007,008 respectively. However, the company's cash reserves stand at $1.11B, which could provide some stability. The debt-to-equity ratio of 55.36 indicates that the company has a relatively high level of indebtedness. The valuation context is notable, with a forward P/E ratio of 239.42 and price to sales ratio of 18.04. The revenue growth rate over the past year has been substantial at 362.0%. However, there are no dividend payments or yields reported for the company.